Supplementary data: Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data

This is a peer-reviewed supplementary table for the article 'Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data' published in the Journal of Comparative Effectiveness Research.Supplementary Table 1: MG treatment definitionsAim: There are limited data on the clinical and economic burden of exacerbations in patients with myasthenia gravis (MG). We assessed patient clinical characteristics, treatments and healthcare resource utilization (HCRU) associated with MG exacerbation. Patients & methods: This was a retrospective analysis of adult patients with MG identified by commercial, Medicare or Medicaid insurance claims from the IBM MarketScan database. Eligible patients had two or more MG diagnosis codes, without evidence of exacerbation or crisis in the baseline period (12 months prior to index [first eligible MG diagnosis]). Clinical characteristics were evaluated at baseline and 12 weeks before each exacerbation. Number of exacerbations, MG treatments and HCRU costs associated with exacerbation were described during a 2-year follow-up period. Results: Among 9352 prevalent MG patients, 34.4% (n = 3218) experienced ≥1 exacerbation after index: commercial, 53.0% (n = 1706); Medicare, 39.4% (n = 1269); and Medicaid, 7.6% (n = 243). During follow-up, the mean (standard deviation) number of exacerbations per commercial and Medicare patient was 3.7 (7.0) and 2.7 (4.1), respectively. At least two exacerbations were experienced by approximately half of commercial and Medicare patients with ≥1 exacerbation. Mean total MGrelated healthcare costs per exacerbation ranged from $26,078 to $51,120, and from $19,903 to $49,967 for commercial and Medicare patients, respectively. AChEI use decreased in patients with multiple exacerbations, while intravenous immunoglobulin use increased with multiple exacerbations. Conclusion: Despite utilization of current treatments for MG,MG exacerbations are associated with a high clinical and economic burden in both commercial and Medicare patients. Additional treatment options and improved disease management may help to reduce exacerbations and disease burden.

此为发表在《比较疗效研究杂志》上的文章《美国重症肌无力患者重症肌无力加重期间医疗资源利用、成本及治疗方案：基于索赔数据的回顾性分析》的同行评审补充表格。补充表格1：重症肌无力治疗方案定义
目标：关于重症肌无力（MG）患者加重期间的临床及经济负担的数据有限。本研究旨在评估与MG加重相关的患者临床特征、治疗方案及医疗资源利用（HCRU）。患者与方法：本研究为对IBM MarketScan数据库中通过商业保险、Medicare或Medicaid索赔记录识别的成年MG患者进行的回顾性分析。符合条件患者具有两个或以上MG诊断代码，基线期（索引诊断前12个月）无加重或危机的证据。在基线及每次加重前12周评估临床特征。在2年随访期间描述与加重相关的加重次数、MG治疗方案及HCRU成本。结果：在9352例MG现症病例中，34.4%（n = 3218）的患者在索引后经历了≥1次加重：商业保险，53.0%（n = 1706）；Medicare，39.4%（n = 1269）；Medicaid，7.6%（n = 243）。在随访期间，商业及Medicare患者平均（标准差）加重次数分别为3.7（7.0）和2.7（4.1）。约一半的具有≥1次加重的商业及Medicare患者经历了至少两次加重。每次加重相关的平均总MG相关医疗成本范围为26,078美元至51,120美元，商业及Medicare患者分别为19,903美元至49,967美元。具有多次加重的患者AChEI的使用减少，而静脉注射免疫球蛋白的使用随着多次加重的增加而增加。结论：尽管目前的治疗方案被应用于MG患者，MG加重仍与商业及Medicare患者的临床及经济负担密切相关。额外的治疗方案及疾病管理的改善可能有助于减少加重及疾病负担。